Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma


S0417 A Phase II Study of Bortezomib (Velcadeā„¢, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma


Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. It may also stop the growth of cancer by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with thalidomide and dexamethasone may kill more cancer cells.


This phase II trial is studying how well giving bortezomib together with thalidomide and dexamethasone works in treating patients with relapsed or refractory multiple myeloma.

Study Status: Terminated


Condition Intervention Phase
Multiple Myeloma Drug: bortezomib
Drug: dexamethasone
Drug: thalidomide
Phase 2

Verified by Southwest Oncology Group March, 2013

Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group identifier: NCT00124579

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States

Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States

Gordan Srkalovic, MD, PhD., Principal Investigator
Mohamad A. Hussein, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site